Perampanel in Real-World Clinical Care of Patients with Epilepsy at Carle Foundation Hospital, Urbana, Illinois: a Regional Comparison of Results from PROVE Study 506

Graham Huesmann, Anna Patten, Manoj Malhotra

1 Carle Foundation Hospital, Urbana, IL, USA; 2 Eisai Ltd., Hatfield, Hertfordshire, UK; 3 Eisai Inc., Woodcliff Lake, NJ, USA

Rationale

- The PROVEn Study investigated regional differences in perampanel efficacy in the real-world clinical care of patients with epilepsy, with the aim of understanding potential regional variability in treatment outcomes.
- The study was conducted at the Carle Foundation Hospital in Urbana, Illinois (Site #1001), and across all other study sites.

Methods

- The study included patients aged 12 years and above, with a diagnosis of epilepsy, who were prescribed perampanel on the basis of their usual epilepsy clinic care.
- The primary efficacy endpoint was the retention rate (proportion of patients in the Safety Analysis Set who remained on perampanel at each successive time point).
- Data were obtained from medical records of patients treated with perampanel and, where available, seizure diaries or investigator assessment of therapeutic response.

Results

- Retention rates at 24 months, proportion of patients with improvement in seizures, and the incidence of TEAEs between Site #1001 and all other sites were compared using a chi-square test.
- Across all other sites, these were irritability (n=48/90), insomnia (n=4/90), and fatigue (n=48/90); across all other sites, these were irritability (n=48/90), insomnia (n=4/90), and fatigue (n=48/90).

Conclusions

- Regional variability in perampanel use may affect regional variability in treatment outcomes.
- Future studies are needed to further investigate regional differences in perampanel efficacy.

References


Acknowledgments

- This work was supported by Eisai USA, Inc., a division of Eisai Inc.
- The authors thank all the patients and their families who participated in the study.
- The authors thank the study sites for their contributions to the study.

Disclosure

- No disclosures.